PLX-4720

Catalog No.S1152

PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Price Stock Quantity  
USD 156 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PLX-4720 Chemical Structure

PLX-4720 Chemical Structure
Molecular Weight: 413.83

Validation & Quality Control

Cited by 45 publications:

9 customer reviews :

Quality Control & MSDS

Related Compound Libraries

PLX-4720 is available in the following compound libraries:

Raf Inhibitors with Unique Features

  • Pan Raf Inhibitor

    AZ 628 Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.

  • Most Potent Raf Inhibitor

    PF-04880594 C-Raf, IC50=0.39 nM; B-Raf, IC50=0.19 nM.

  • FDA-approved Raf Inhibitor

    Sorafenib Tosylate Approved by FDA for advanced renal cancer。

  • Newest Raf Inhibitor

    TAK-632 Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Product Information

  • Compare Raf Inhibitors
    Compare Raf Products
  • Research Area
  • Inhibition Profile
  • PLX-4720 Mechanism

Product Description

Biological Activity

Description PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
Targets C-Raf-1 (Y340D/Y341D) [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
BRK [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)

 View  More

IC50 6.7 nM 13 nM 130 nM 160 nM
In vitro PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-RafV600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-RafV600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-RafV600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. [1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN+ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN- cells to PLX-4720-induced apoptosis. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
DU-4475MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;pTWM2OD1yLkC3OFU4KM7:TR?=NVGwXWJyW0GQR1XS
EoL-1-cellNVfoXGJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTBwMUSxOlYh|ryPMoP6V2FPT0WU
C32MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfYb3d6UUN3ME2wMlE2OTNzIN88US=>M4C0[3NCVkeHUh?=
M14NHHSZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7lTWM2OD1yLkKxO|U4KM7:TR?=MVLTRW5ITVJ?
CP50-MEL-BMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTBwMkm3PFQh|ryPM4DTW3NCVkeHUh?=
A101DMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXIOlJKSzVyPUCuN|I2QDlizszNM{TIVnNCVkeHUh?=
G-361NX\zNIZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnz5TWM2OD1yLkO0OlM4KM7:TR?=NW\ESFhxW0GQR1XS
HT-144NWfnNWNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHWR4tuUUN3ME2wMlM3OzJ7IN88US=>NIXUUFhUSU6JRWK=
ACNMkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDPXnlKSzVyPUCuN|g1PzdizszNMVvTRW5ITVJ?
COLO-829NVnwUmhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYKyd3ZLUUN3ME2wMlM5QTZ6IN88US=>MYfTRW5ITVJ?
MEL-HONVyyU|ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vZcGlEPTB;MD60NVE4QSEQvF2=M3vpPHNCVkeHUh?=
SH-4NWPNbYtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPkTFlKSzVyPUCuOFE1OjJizszNNIToSndUSU6JRWK=
SK-MEL-3M1T4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHH4dlZKSzVyPUCuOVE2PjhizszNMn[wV2FPT0WU
A375M2nVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE[0UolKSzVyPUCuOlc{PTlizszNMU\TRW5ITVJ?
MMAC-SFNVvibVR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\1VGlEPTB;MD62PFYyPCEQvF2=MUjTRW5ITVJ?
BHT-101MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PGR2lEPTB;MD63NFcxOiEQvF2=M2P1VXNCVkeHUh?=
K5NYT0R2g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTBwN{[xOFgh|ryPNEi4WW9USU6JRWK=
BV-173MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3vTWM2OD1yLke5OlQ1KM7:TR?=NIG4UFhUSU6JRWK=
RVH-421NEfPTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTBwOE[3PVYh|ryPMlTaV2FPT0WU
HCC2218MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTBwOEe4OFQh|ryPMlzMV2FPT0WU
WM-115M1fVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPofHNKSzVyPUCuPFg3QTJizszNNIT6XVlUSU6JRWK=
SK-MEL-28MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rQXmlEPTB;MT6wOFU3QSEQvF2=MoLXV2FPT0WU
COLO-679MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTLXlhVUUN3ME2xMlExPDZ2IN88US=>MorOV2FPT0WU
MZ7-melNGHONVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUX1[HhPUUN3ME2xMlE1QTZ|IN88US=>MnTWV2FPT0WU
SK-MEL-30MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrZUGJUUUN3ME2xMlM{Ozh4IN88US=>MnTtV2FPT0WU
NCI-H209M4XwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\FTWM2OD1zLk[wPFYh|ryPNGjFUlFUSU6JRWK=
HTC-C3M2HKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTFwNk[yPVQh|ryPMkW4V2FPT0WU
KARPAS-45M3rQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PEdWlEPTB;Mj6wOFk4QCEQvF2=MVXTRW5ITVJ?
NCI-SNU-5MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnK5TWM2OD1{LkGxPVY6KM7:TR?=NWDHUVNqW0GQR1XS
KP-4MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPPTWM2OD1{LkOwO|g4KM7:TR?=MlrNV2FPT0WU
PA-1MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfxVHBKSzVyPUKuO|I3PzNizszNNIXITHBUSU6JRWK=
HuO-3N1M1XVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4G0[GlEPTB;Mj64O|k1PiEQvF2=MmTvV2FPT0WU
NCI-H358NIjQXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rtOGlEPTB;Mj65NlI{OiEQvF2=Mkj1V2FPT0WU
CTB-1NVTVZ2hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLRb4lKSzVyPUOuOFAyPzZizszNM{Lpe3NCVkeHUh?=
697Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTNwNUWyOlYh|ryPMn\YV2FPT0WU
CP66-MELM1nwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTRwMUW5Nlch|ryPM37yOXNCVkeHUh?=
NB13NWnFTZFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHETWM2OD12LkS5NVc6KM7:TR?=Ml2wV2FPT0WU
DBTRG-05MGNVqwVGpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTRwNUOzNlUh|ryPM4nET3NCVkeHUh?=
A2058NWfTWZB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PxXGlEPTB;ND63NlE3PCEQvF2=MlTNV2FPT0WU
KG-1NVfH[YVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnq5TWM2OD12LkezPVA5KM7:TR?=NES4WFdUSU6JRWK=
8305CM4rzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDaTWM2OD13LkG4O|Mh|ryPNXXIT|dSW0GQR1XS
RPMI-7951MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTVwOECyPFMh|ryPMXvTRW5ITVJ?
CHL-1NWnxdnEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIS4eWhKSzVyPUWuPVc3ODNizszNNITNS2dUSU6JRWK=
TI-73MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mli0TWM2OD14LkCwPVAzKM7:TR?=M{TEN3NCVkeHUh?=
HT-1080MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF73VHRKSzVyPU[uNVA6PDZizszNNEnBXW1USU6JRWK=
ES5M2DqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTZwMUS5NlQh|ryPM4rBTnNCVkeHUh?=
8-MG-BANI\RT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTZwMUixNlkh|ryPMlP0V2FPT0WU
NB7MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXWcI5KSzVyPU[uNlE{PzNizszNNYLNbm04W0GQR1XS
H4MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTZwMkK0PVMh|ryPMnLwV2FPT0WU
CAL-72MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rqXWlEPTB;Nj60OVQzOyEQvF2=NGnJTWhUSU6JRWK=
HCC1806NYXab4FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILGT3VKSzVyPU[uPFE6OzFizszNM3fU[nNCVkeHUh?=
BCPAPNIPKS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDEc2FKSzVyPUeuNlE4PjRizszNNYLqd5BQW0GQR1XS
LB2241-RCCMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnRe3JKSzVyPUeuN|Y6ODdizszNMofjV2FPT0WU
COLO-741NWP1W49zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETXbVJKSzVyPUiuNFE3PzlizszNM4D5[3NCVkeHUh?=
HSC-3MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;WWGlEPTB;OD6wO|A3QCEQvF2=NHvleYRUSU6JRWK=
SW982M3HlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRThwNEG1NVYh|ryPMYPTRW5ITVJ?
GCTMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\Mb3FKSzVyPUiuO|U{OTRizszNM1jOeXNCVkeHUh?=
KY821MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXuzSmh1UUN3ME25MlA2OTd6IN88US=>MVnTRW5ITVJ?
JVM-3NEnoUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFj1d5lKSzVyPUmuOVY6QTlizszNMoi5V2FPT0WU
RS4-11NV\tR5dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIn2N3dKSzVyPUmuOlA1QCEQvF2=NIntdIxUSU6JRWK=
VA-ES-BJNXPjUpdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zZSWlEPTB;MUCuNFE1QSEQvF2=NX;JZo9yW0GQR1XS
A431NXXUR5RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEO4W|JKSzVyPUGwMlQzOTJizszNM{P0S3NCVkeHUh?=
LXF-289NGnwXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1ric2lEPTB;MUCuOFU5KM7:TR?=NUPmZmZvW0GQR1XS
SK-MEL-24MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTFyLkiyO|Qh|ryPNUT3b25yW0GQR1XS
NOS-1M1fWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nXWmlEPTB;MUCuPFQ4OiEQvF2=MVLTRW5ITVJ?
KNS-62Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHj1empKSzVyPUGxMlI1ODRizszNNUfXVmZLW0GQR1XS
SK-HEP-1NIC2dmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7ZUGVHUUN3ME2xNU4{PTJ5IN88US=>M1K0d3NCVkeHUh?=
A3-KAWNFGwUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTyTpNKSzVyPUGxMlcyPzhizszNNYr1d5RKW0GQR1XS
SK-LU-1Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37O[2lEPTB;MUKuNlY2PSEQvF2=Ml7oV2FPT0WU
TYK-nuMnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\4PFlKUUN3ME2xNk4{QTN{IN88US=>M3nlcHNCVkeHUh?=
NMC-G1NITCXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTF{Lk[wOlIh|ryPMlfXV2FPT0WU
BB65-RCCMnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\pNpBpUUN3ME2xNk44OTZ7IN88US=>M2TSUHNCVkeHUh?=
QIMR-WILMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2qyUmlEPTB;MUKuPFg{OyEQvF2=NWDWdohKW0GQR1XS
D-566MGMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDWTWM2OD1zMz65OVc3KM7:TR?=NVjkWIdmW0GQR1XS
KYSE-140NVy2[lFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXOTWM2OD1zND6wO|U{KM7:TR?=NVi4[W5NW0GQR1XS
SCC-4MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfyfYNRUUN3ME2xOE4{OzV7IN88US=>NVXjT|ZjW0GQR1XS
U251NVe3R5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE[yPGhKSzVyPUG0Mlg1QTJizszNNGP6W3hUSU6JRWK=
D-542MGMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrjTWM2OD1zND65NlIzKM7:TR?=NVG4fIdQW0GQR1XS
LAMA-84NV7pbYViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDTcFZ[UUN3ME2xOE46QTN{IN88US=>MnHJV2FPT0WU
NCI-H720M1PzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3YTWM2OD1zNT6yOlg1KM7:TR?=M1:1V3NCVkeHUh?=
DELNWjpRmh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HjbWlEPTB;MUWuOFI6OyEQvF2=MlvpV2FPT0WU
SBC-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7aOFZWUUN3ME2xOU41OzB3IN88US=>NVGwTIhnW0GQR1XS
ECC10M1PLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\4Uo1KSzVyPUG1MlQ1PThizszNNWnkTHQ3W0GQR1XS
DaoyM1XCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPxTJNYUUN3ME2xOU44PjF4IN88US=>MX7TRW5ITVJ?
SCHMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfYRodKSzVyPUG1Mlc5OzVizszNNH7Uc5NUSU6JRWK=
MZ2-MELM3X3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF[weZJKSzVyPUG2MlA3PDZizszNNE\OdlBUSU6JRWK=
CAL-12TNI\ZWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\ZRWlEPTB;MU[uOFg3OiEQvF2=MXPTRW5ITVJ?
KE-37MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFS0VZRKSzVyPUG2MlgyODdizszNNH3NbWhUSU6JRWK=
LS-411NMkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXB[mxbUUN3ME2xO{4yOThizszNMXPTRW5ITVJ?
NCI-H2228MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTF5LkOwO|Eh|ryPNHfIc5RUSU6JRWK=
SK-MEL-2MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfIWoFKSzVyPUG3MlQ6PjVizszNMlTvV2FPT0WU
HNNFLKepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPrc3pwUUN3ME2xO{44OjR6IN88US=>NXL6cmFiW0GQR1XS
NCI-H1648NF\EXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\4dlhKSzVyPUG3MlgyQCEQvF2=M4f6d3NCVkeHUh?=
IA-LMNHXlTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnX6TWM2OD1zOD6zNVczKM7:TR?=NIToW5hUSU6JRWK=
EW-13MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlmyTWM2OD1zOD61O|A5KM7:TR?=Mke5V2FPT0WU
YKG-1NFfzPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHSUI9KSzVyPUG5MlU4OTFizszNNFOzV29USU6JRWK=
KNS-81-FDNES3fWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTF7LkW4OVgh|ryPM4qyOXNCVkeHUh?=
23132-87MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vqXWlEPTB;MUmuO|Y1OiEQvF2=MYLTRW5ITVJ?
NUGC-3NILUWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;5bY1[UUN3ME2xPU46QDh5IN88US=>M{DCcHNCVkeHUh?=
5637NY\zZmJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7w[FNKSzVyPUKwMlA1PzhizszNMnTJV2FPT0WU
NCI-H1755MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HMb2lEPTB;MkCuOFc3PCEQvF2=Mkn1V2FPT0WU
RH-18NXe2WXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH:xc5JKSzVyPUKwMlU4PDhizszNMXjTRW5ITVJ?
RXF393NYCwSVNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\OTWM2OD1{MD62O|U3KM7:TR?=NX7TcYNDW0GQR1XS
LU-134-AMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVKzN4VWUUN3ME2yNE44ODV4IN88US=>NU[zVIFjW0GQR1XS
TE-12M2XQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{H2[GlEPTB;MkCuO|IxOSEQvF2=NVXVXVhEW0GQR1XS
MOLT-4NVHGWWlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXr3epNYUUN3ME2yNU4yQTF3IN88US=>NUXJd3p7W0GQR1XS
IGR-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHOZ|k2UUN3ME2yNU4{Pzl4IN88US=>M3f2W3NCVkeHUh?=
HOP-92M1rrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTJzLkS5PFch|ryPNGr5eFRUSU6JRWK=
SK-MES-1NIL3S3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTrbZByUUN3ME2yNU44OzhzIN88US=>M{nlWXNCVkeHUh?=
LU-65NEOxfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITaTVZKSzVyPUKxMlg3OjRizszNMoriV2FPT0WU
MS-1M3;KO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLMZ2hVUUN3ME2yNk4yOjB|IN88US=>M37kRXNCVkeHUh?=
LoVoNXzt[4wyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2n0Z2lEPTB;MkKuNlQ1KM7:TR?=NYSxcY9xW0GQR1XS
A704MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTHcJF1UUN3ME2yNk42OTV3IN88US=>NX[xSnRIW0GQR1XS
HT-1376Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\s[IRvUUN3ME2yNk43ODV7IN88US=>MnPqV2FPT0WU
IST-MEL1Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1[3V2lEPTB;MkKuOlc2OSEQvF2=MXLTRW5ITVJ?
Ramos-2G6-4C10MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPE[G1KSzVyPUKyMlc{PjZizszNNFPrXY9USU6JRWK=
T47DNUj5SplYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTJ{Lke5O|kh|ryPNWW0UmZ3W0GQR1XS
HT-1197NHmwO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTJ|LkC4NVch|ryPNH\DUmNUSU6JRWK=
LB2518-MELMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7ZTWM2OD1{Mz62OFEzKM7:TR?=NVPHfZN6W0GQR1XS
J-RT3-T3-5NVfkRoJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzwNFJKSzVyPUK0Mlc2QTVizszNMmnUV2FPT0WU
SK-NEP-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTRTWM2OD1{ND64O|Q1KM7:TR?=MU\TRW5ITVJ?
NCI-H526Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\vSGp5UUN3ME2yOU4xODJ|IN88US=>Mmj1V2FPT0WU
IST-SL1NF;PSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYmzTopMUUN3ME2yOU4zPzVzIN88US=>M4PCeHNCVkeHUh?=
HHNYn0SXZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUGx[5pbUUN3ME2yOU4{OTl{IN88US=>NGXIeXZUSU6JRWK=
NCI-H82MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDJcIVwUUN3ME2yOU46OzhizszNM4H2SXNCVkeHUh?=
SNU-449M3K3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjWTWM2OD1{Nz6yNFE5KM7:TR?=MUXTRW5ITVJ?
COR-L23MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jkWGlEPTB;MkeuNlgyOyEQvF2=NFmyRZVUSU6JRWK=
LOXIMVIMlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HPN2lEPTB;MkeuN|Y5KM7:TR?=NXn0SmtPW0GQR1XS
GR-STMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTJ5Lk[3NFYh|ryPMof1V2FPT0WU
NCI-SNU-1MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTJ5Lkm0OEDPxE1?MYrTRW5ITVJ?
ALL-POM1n4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfRPVBqUUN3ME2yPE4yPjB2IN88US=>NU\IcINwW0GQR1XS
ML-2MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTJ6LkK4NVQh|ryPMmi4V2FPT0WU
HOP-62NYnrcY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2qzbGlEPTB;MkiuO|E{KM7:TR?=MUnTRW5ITVJ?
EGI-1NYfBZZNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITtZlBKSzVyPUK4Mlg5PDVizszNMkPGV2FPT0WU
TCCSUPMnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHza[3NKSzVyPUK4MlkzPzJizszNM4HUO3NCVkeHUh?=
LB996-RCCM3W4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTJ7LkW2PFIh|ryPMnv2V2FPT0WU
LCLC-97TM1MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7vXWpjUUN3ME2zNk4yQTZ2IN88US=>NYf6[XZ3W0GQR1XS
NCI-H1304MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPQV|BKSzVyPUOyMlM{ODFizszNMYDTRW5ITVJ?
KP-N-YSNIPxVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\C[Yt1UUN3ME2zNk42QTd|IN88US=>M2q1N3NCVkeHUh?=
NCI-H1770MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLyTWM2OD1|Mz6xOlQ5KM7:TR?=MWDTRW5ITVJ?
EM-2M1fMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFS2OJBKSzVyPUOzMlY2ODRizszNMmjyV2FPT0WU
ChaGo-K-1M3nROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfMTWM2OD1|Mz63NlM3KM7:TR?=M2jNSnNCVkeHUh?=
ACHNMlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX63fW5KUUN3ME2zN{45Ozh3IN88US=>MUDTRW5ITVJ?
MN-60M133[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37hOmlEPTB;M{OuPFU1PCEQvF2=MXfTRW5ITVJ?
EW-18NVe2SJJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrWOXFKSzVyPUOzMlg6PzFizszNNILWblRUSU6JRWK=
KGNMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXJNHJZUUN3ME2zOU44Ojl{IN88US=>MYPTRW5ITVJ?
U031MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjRTWM2OD1|NT64NVMzKM7:TR?=M3mxUnNCVkeHUh?=
HMV-IINUXD[oZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFyzd3VKSzVyPUO2MlA4PzRizszNMXfTRW5ITVJ?
L-363MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTNVXNoUUN3ME2zO{43PDV3IN88US=>M1\pfXNCVkeHUh?=
NCI-H1155NIPvNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnaR4NKSzVyPUO4MlAxOTVizszNNHfxTYlUSU6JRWK=
NCI-H1793MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXvd2tVUUN3ME2zPE4yODJ4IN88US=>NGHpZotUSU6JRWK=
P30-OHKNGnlUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHGPZBKSzVyPUO4MlE{OzJizszNMYXTRW5ITVJ?
AN3-CAMoq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTpTWM2OD1|OD6xOlE2KM7:TR?=NFfkVnZUSU6JRWK=
UACC-257MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XmUmlEPTB;M{iuO|kh|ryPMny4V2FPT0WU
MCF7MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTN7Lki2Nlkh|ryPNFr1[ldUSU6JRWK=
KP-N-YNNGTwTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HNZ2lEPTB;NECuOFI5PSEQvF2=MVnTRW5ITVJ?
T98GNEHuUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3STWM2OD12MD60PVU4KM7:TR?=MX\TRW5ITVJ?
HGC-27NH7Md|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTR|LkK3OEDPxE1?M3;aUHNCVkeHUh?=
NCI-H1092NY\EWJd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTR|LkK4PVUh|ryPMkLLV2FPT0WU
KARPAS-299NGrGW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3YV|JKSzVyPUSzMlMxPzFizszNMYDTRW5ITVJ?
LB1047-RCCM4Dve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTR2Lkm5OVkh|ryPNWPkRpd[W0GQR1XS
786-0NX;aPHM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fGUGlEPTB;NEWuOlUh|ryPMom0V2FPT0WU
HCC2157MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TNR2lEPTB;NE[uNFM2QSEQvF2=NHP3[45USU6JRWK=
NYNIGxT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LnWGlEPTB;NE[uNVc4QCEQvF2=M1nkU3NCVkeHUh?=
EFM-19MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PxSGlEPTB;NE[uO|U{OyEQvF2=MVXTRW5ITVJ?
EW-16MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlOxTWM2OD12Nj63PFA3KM7:TR?=NVS1PZJSW0GQR1XS
UM-UC-3M3[weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXBVZFwUUN3ME20Ok45ODV7IN88US=>NHThTXFUSU6JRWK=
HT-29NUHuXGJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TTfmlEPTB;NEeuPFc6OiEQvF2=NUC0ZpdiW0GQR1XS
LN-405MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrvTWM2OD12OD6wPFI4KM7:TR?=MULTRW5ITVJ?
NCI-H727NH;CXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWr2cmJqUUN3ME20PE44PzJ4IN88US=>Ml;5V2FPT0WU
D-502MGNYLH[VV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\IWm9KSzVyPUS4Mlk3PzZizszNNW\RWFVwW0GQR1XS
GMS-10MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPCZYtKUUN3ME20PU4zQTd2IN88US=>M2TNfHNCVkeHUh?=
MEL-JUSONEXodG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XYZmlEPTB;NEmuN|Q4KM7:TR?=MXfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-RafV600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-RafV600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. [1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. [3]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro Raf kinase activities The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.

Cell Assay: [1]

Cell lines COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells
Concentrations Dissolved in DMSO, final concentrations ~1 mM
Incubation Time 24, 48, and 72 hours
Method Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus.

Animal Study: [1]

Animal Models Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells
Formulation Suspended in vehicle (5% DMSO, 1% methylcellulose)
Dosages 5, 20, or 100 mg/kg
Administration Oral gavage once or twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tsai J, et al. Proc Natl Acad Sci U S A, 2008, 105(8), 3041-3046.

[2] Paraiso KH, et al. Cancer Res, 2011, 71(7), 2750-2760.

view more

Chemical Information

Download PLX-4720 SDF
Molecular Weight (MW) 413.83
Formula

C17H14ClF2N3O3S

CAS No. 918505-84-7
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 83 mg/mL (200.56 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+50% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide

Frequently Asked Questions

  • Question 1
    What would you recommend to make working solution for intraperitoneal injection into mice?

    Answer: PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Raf Products

  • LY3009120

    LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.

  • GDC-0994

    GDC-0994 is a potent, orally available ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.

  • Ulixertinib (BVD-523, VRT752271)

    Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.

  • Vemurafenib (PLX4032, RG7204)

    Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay.

    Features:A novel and potent inhibitor of the B-RAFV600E oncoprotein.

  • Dabrafenib (GSK2118436)

    Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.

  • Sorafenib

    Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

  • Sorafenib Tosylate

    Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

  • TAK-632

    TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.

  • GDC-0879

    GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.

  • GW5074

    GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Recently Viewed Items

Tags: buy PLX-4720 | PLX-4720 supplier | purchase PLX-4720 | PLX-4720 cost | PLX-4720 manufacturer | order PLX-4720 | PLX-4720 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us